Merck Millipore Introduces Single-Pass Tangential Flow Filtration with Pellicon Cassettes® for Increased Capacity, Recovery and Concentration

• A simpler way to reduce processing volumes and eliminate process bottlenecks
• Reduction in pump size and less hardware, resulting in lower cost and a more compact footprint
• Allows higher concentration factors and higher product recovery

Merck Millipore, the Life Science business of Merck, today introduced single-pass tangential flow filtration (TFF) with Pellicon^® cassettes, an enhanced application of Merck Millipore's existing TFF technology that allows concentration of process streams without the recirculation required in traditional TFF. This alternative application eliminates typical process constraints caused by higher volumes or concentration factors, resulting in increased capacity. It also enables continuous processing by coupling the TFF step in-line with other process steps.

"Tangential flow filtration is widely used by biopharmaceutical manufacturers for downstream concentration, and the industry can benefit from new ways to simplify the process," said Daniel Stamm, Head of Global Pharma Processing. "Merck Millipore has been collaborating with its customers on single-pass TFF process development, allowing them to meet the demands of higher titer processes without major investments in new equipment with great success."

Merck Millipore's single-pass TFF system uses its proven Pellicon^® cassettes, which are TFF devices ideal for higher titer therapeutic antibodies as well as more demanding filtration processes that require higher operating pressures, temperatures, concentrations or caustic cleaning regimes. The cassettes deliver unmatched performance consistency and have been used by Merck Millipore customers worldwide at every stage and scale of biopharmaceutical production.